OncoMatch/Clinical Trials/DIPG / Diffuse Midline Glioma
DIPG / Diffuse Midline Glioma Clinical Trials
OncoMatch filters DIPG / Diffuse Midline Glioma trials by the molecular markers that determine eligibility — H3-3A, ACVR1, PPM1D, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout DIPG / Diffuse Midline Glioma trials
DIPG (now classified more broadly as diffuse midline glioma, DMG, under WHO 2021 criteria) is defined molecularly by H3 K27M-altered status. H3-3A (encoding histone H3.3) carries the K27M mutation in roughly 80% of DIPG cases; the H3.1 variant (encoded by HIST1H3B/C, not in this panel) accounts for most of the rest. ACVR1 mutations occur in about 25% of DIPG, often co-occurring with H3.1 K27M and driving aberrant BMP signaling. PPM1D phosphatase mutations occur in 10-15% and contribute to treatment-resistance biology.
Trial selection in DIPG and DMG depends on age, tumor location, and H3 K27M status. Imipridone-class trials (following the 2025 accelerated approval of dordaviprone for progressive H3 K27M-mutant DMG after prior therapy) are an active targeted-therapy space, with combinations and earlier-line use in development. ACVR1 inhibitor trials enroll the ACVR1-mutant subset, particularly common in younger patients. Re-irradiation trials test repeat radiation strategies for progression after initial focal radiation. CAR-T trials directed at B7-H3 or GD2 are an active emerging area distinct from the blood-cancer CAR-T space. Convection-enhanced delivery (CED) trials test direct intratumoral delivery of agents that don't cross the blood-brain barrier well. Combination trials test radiation with targeted agents to extend response duration.
DIPG / DMG trial screening typically checks H3 K27M status, age, and prior radiation exposure. Tumor location (classic pontine DIPG vs other midline locations like thalamus or spinal cord) gates some trials and determines surgical accessibility. H3 K27M mutation confirmation is required for imipridone-class trials. Prior radiation dose and field for re-irradiation eligibility (typically requires sufficient time and dose-volume thresholds). Steroid dose, with many trials capping dexamethasone for IO and vaccine trials. Performance status using Lansky scale for younger patients or Karnofsky for older. Age cutoffs vary widely: pediatric trials typically include patients up to 18 or 21, while DMG trials in young adults are often separate.
Biomarkers tested in DIPG / Diffuse Midline Glioma trials
These are the molecular markers most commonly required or evaluated in DIPG / Diffuse Midline Glioma eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting DIPG / Diffuse Midline Glioma trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Gustave Roussy, Cancer Campus, Grand Paris
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of California, San Francisco
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Nationwide Children's Hospital
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
How OncoMatch finds DIPG / Diffuse Midline Glioma trials for you
AI reads the protocol
Every DIPG / Diffuse Midline Glioma trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select DIPG / Diffuse Midline Glioma and mark your biomarker results — H3-3A, ACVR1, PPM1D — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.